Novartis Hellas SACI
12th km National Road Athens-Lamia, Metamorfosi, 144 51 Athens, Greece
COVID-19 Novartis response
Donations, External collaborations, Internal discovery and Clinical investigations
In the face of a global crisis, Novartis has quickly mobilized R&D capabilities, medicines, clinical trials expertise and philanthropic aid to address the coronavirus pandemic.
Contributions upwards of USD 40 million to over 60 projects around the world that support local communities impacted by this crisis. These include major donations to strengthen medical infrastructure and provide on-site support in many countries.
Commitment to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response. Sandoz, the Novartis generics and biosimilars division, is also maintaining prices on a basket of essential medicines that may help in the treatment of COVID-19.
We are undertaking several efforts to leverage our capabilities in discovery, development and scale-up manufacturing. We are partnering with multi-stakeholder external consortia, including:
- COVID-19 Therapeutics Accelerator, coordinated by the Bill & Melinda Gates Foundation, Wellcome Trust and MasterCard
- COVID-19 direct partnership organized by Innovative Medicines Initiative
- ACTIV partnership planned by National Institutes of Health
- Member of R&D Leaders Consortium
- Drug discovery efforts with the University of California, Berkeley
Novartis is leading, partnering and supporting the identification of therapeutic candidates against coronavirus. We have hand-selected a library of compounds with activity against viral targets of relevance to COVID-19, and we’re working with a consortium of academic institutions and companies that is looking to screen compounds at an appropriate laboratory facility.
We are also spearheading a collaborative effort to make direct-acting anti-viral compounds to the coronavirus family, including COVID-19, SARS and MERS. This early-stage drug discovery work builds on the collaboration that formed the Novartis-Berkeley Center for Proteomics and Chemistry Technologies. The new open-science effort will target a piece of machinery that’s shared by several known coronaviruses.
Together with the research community, Novartis is assessing whether our clinical-stage investigational or approved medicines could be repurposed beyond their intended or approved indications to treat complications of COVID-19 disease.
Novartis plans to sponsor or co-sponsor multiple large clinical trials of its existing medicines as COVID-19 treatments, including hydroxychloroquine as well as Jakavi® (ruxolitinib), in collaboration with Incyte, and Ilaris® (canakinumab).
Images and article source: https://www.novartis.com/coronavirus/response